Investigating the Role of GABA in Neural Development and Disease Using Mice Lacking GAD67 or VGAT Genes

• Published in: International journal of molecular sciences Vol. 23; no. 14; p. 7965
• Main Authors: Bolneo, Erika, Chau, Pak Yan S., Noakes, Peter G., Bellingham, Mark C.
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 19.07.2022; MDPI
• Subjects: Autism; Binding sites; Brain; Cell cycle; Central nervous system; Chloride channels; Epilepsy; Forebrain; GABA; GABA-receptors; GABAergic transmission; GAD65; GAD67; Mental disorders; Nervous system; Neurogenesis; Neurological diseases; Neurons; Neurotransmission; Neurotransmitters; Review; Schizophrenia; Signal transduction; Spinal cord; Synapses; VGAT; γ-Aminobutyric acid; γ-Aminobutyric acid receptors
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms23147965

Normal development and function of the central nervous system involves a balance between excitatory and inhibitory neurotransmission. Activity of both excitatory and inhibitory neurons is modulated by inhibitory signalling of the GABAergic and glycinergic systems. Mechanisms that regulate formation, maturation, refinement, and maintenance of inhibitory synapses are established in early life. Deviations from ideal excitatory and inhibitory balance, such as down-regulated inhibition, are linked with many neurological diseases, including epilepsy, schizophrenia, anxiety, and autism spectrum disorders. In the mammalian forebrain, GABA is the primary inhibitory neurotransmitter, binding to GABA receptors, opening chloride channels and hyperpolarizing the cell. We review the involvement of down-regulated inhibitory signalling in neurological disorders, possible mechanisms for disease progression, and targets for therapeutic intervention. We conclude that transgenic models of disrupted inhibitory signalling—in GAD67+/− and VGAT−/− mice—are useful for investigating the effects of down-regulated inhibitory signalling in a range of neurological diseases.